# Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors

> **NCT01898416** · PHASE2 · RECRUITING · sponsor: **michal roll** · enrollment: 140 (estimated)

## Conditions studied

- The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an
- Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After
- Surgical Resection

## Interventions

- **DRUG:** 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.

## Key facts

- **NCT ID:** NCT01898416
- **Lead sponsor:** michal roll
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2013-06
- **Primary completion:** 2023-12
- **Final completion:** 2026-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2013-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01898416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01898416, "Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01898416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*